-
Presenter Profile: Lipoproteins and Insulin Sensitivity: Focus on ApoB and Lp(a)
Gissette Reyes-Soffer, MD, FAHA, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Saturday, June 6, at 8:00 a.m. CT.
-
Presenter Profile: Targeting the Source: Aldosterone Synthase Inhibitors in Diabetic Kidney Disease
Peter Rossing, MD, DMSc, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Saturday, June 6, at 8:00 a.m. CT.
-
Presenter Profile: How Low to Go? And in Whom? New Blood Pressure Targets in Diabetes
Daniel W. Jones, MD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Sunday, June 7, at 8:00 a.m. CT.
-
Presenter Profile: Pharmacotherapy Considerations
Elena Toschi, MD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Friday, June 5, at 3:45 p.m. CT.
-
Presenter Profile: Leveraging Artificial Intelligence for Precision Medicine in Youth-Onset Type 2 Diabetes
Mustafa Tosur, MD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Sunday, June 7, at 8:00 a.m. CT.
-
Presenter Profile: Next-Generation Pharmacotherapies to Reduce Hypoglycemia
Matthew J. Webber, PhD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Sunday, June 7, at 1:30 p.m. CT.
-
Presenter Profile: Understanding Diabetes Heterogeneity via Mining Multimodality Interconnected Data
Carl Yang, PhD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Sunday, June 7, at 8:00 a.m. CT.
-
Investigators to bring data on glucose management with oral orforglipron
Julio Rosenstock, MD, Francesco Giorgino, MD, PhD, and other panelists will discuss results from the ACHIEVE clinical trials, including ACHIEVE-3, which compared oral semaglutide and orforglipron for use in type 2 diabetes.
-
Researchers to share VESPER phase 2 clinical trial data
Investigators, including John B. Buse, MD, PhD, will discuss new insights from the VESPER program examining berobenatide, an ultra-long-acting glucagon-like peptide-1 (GLP-1) receptor agonist for weight management.
-
Experts to discuss the benefits of glucagon/GLP-1 receptor dual agonism gleaned from SYNCHRONIZE
Lee Kaplan, MD, PhD, and other investigators will examine the basic science underlying injectable survodutide, as well as results from two of the four studies in the SYNCHRONIZE program.